Chiari Malformations

• Posterior fossa crowding and reduced CSF space: Type I CM involves downward displacement of cerebellar tonsils (>5 mm below the foramen magnum) into the cervical spinal canal, typically resulting from inadequate posterior fossa volume relative to its contents. This is most commonly due to occipital bone hypoplasia, shortened clivus, or small posterior fossa rather than primary cerebellar enlargement. The crowding mechanism creates a Venturi effect where CSF flow acceleration through the narrow foramen magnum generates negative pressure, further drawing cerebellar tissue caudally.

• CSF dynamics disruption and syrinx formation: The mechanical obstruction to CSF flow results in impaired compliance and pressure oscillations transmitted to the spinal cord, particularly during cardiac pulsations and Valsalva maneuvers. This pulsatile pressure gradient drives fluid penetration into the cord parenchyma, forming a syrinx (often seen in 50–80% of symptomatic Type I cases). The syrinx may represent either CSF-filled cavitation (communicating with the central canal) or edema from chronic ischemia and inflammatory changes. Progressive syrinx expansion correlates with advancing neurological deficits.

• Mechanical compression and vascular compromise: Direct pressure from herniated cerebellar tissue compresses ascending spinothalamic fibers and descending corticospinal tracts, producing a suspended sensory level with characteristic "cape-like" distribution of pain and temperature loss. Compression of arterial feeders and alteration of spinal cord microvascular perfusion contributes to chronic ischemia, neuronal apoptosis, and gliosis. Compression of lower cranial nerves (CN IX–XII) at the foramen magnum may result in dysphagia, dysarthria, and vocal cord dysfunction.

Congenital (Primary) Chiari Malformations

• Type I: Associated with occipital bone hypoplasia, basilar invagination, tethered spinal cord, syringomyelia, and atlanto-axial instability. Risk factors include genetic predisposition (familial cases reported in 5–10% of patients), though most are sporadic. Associated conditions include Ehlers-Danlos syndrome, Marfan syndrome, osteogenesis imperfecta, and achondroplasia.

• Type II: Always associated with myelomeningocele (open neural tube defect); involves greater cerebellar displacement and brainstem herniation compared to Type I.

• Type III: Rare variant with occipital encephalocele containing herniated cerebellar tissue; incompatible with normal neurological function.

• Type IV: Cerebellar hypoplasia with caudal displacement; the least common and most severe variant.

Acquired (Secondary) Chiari Malformations

• Increased intracranial pressure from mass lesions (tumors, hematomas), hydrocephalus, pseudotumor cerebri, or arachnoid cysts pushing neural tissue caudally.

• Tethered spinal cord: Anchoring of the cord restricts rostral movement, increasing relative crowding of the posterior fossa.

• Syrinx-associated: Chronic arachnoiditis, spinal cord trauma (post-traumatic syrinx), tethering, or arachnoid scarring from prior surgery or inflammation.

• Cardinal symptoms:
• Occipital headaches: Most frequent symptom (60–90% of symptomatic patients); often triggered by Valsalva maneuvers (coughing, straining, sneezing), positional changes, or exertion; characteristically worse with neck flexion due to increased CSF pressure transmission
• Neck pain: Present in 40–60% of patients; may have a radicular quality
• Progressive myelopathic symptoms: Weakness, spasticity, and hyperreflexia (particularly in lower extremities)
• Sensory disturbances: Classic "cape-like" or "shawl" distribution of pain and temperature loss affecting shoulders, arms, and upper back (due to compression of crossing spinothalamic fibers in the anterior commissure at the level of the syrinx)
• Neuropathic pain and dysesthesias: Often severe and progressive
• Lower cranial nerve dysfunction: Dysphagia, dysarthria, vocal cord paralysis, atrophy of tongue (CN XII involvement)

• Physical examination findings:
• Hyperreflexia and spasticity in lower extremities (indicating upper motor neuron involvement)
• Weakness in upper extremities (both proximal and distal), sometimes with atrophic changes (lower motor neuron component from anterior horn cell involvement)
• Sensory level with suspended sensory deficit (normal sensation distally below a specific level, but impaired sensation at a higher level—pathognomonic for intramedullary pathology)
• Nystagmus (particularly downbeating, from brainstem compression)
• Romberg sign positivity (posterior column involvement)
• Weakness of shoulder shrug and neck weakness (CN XI involvement)
• Lhermitte sign: Electric shock sensation down the spine with neck flexion

• Asymptomatic presentation:
• Incidental discovery of cerebellar tonsillar herniation on neuroimaging performed for unrelated indications; accounts for 20–50% of Type I cases at diagnosis
• Asymptomatic patients generally do NOT require prophylactic surgery, though regular clinical and radiological surveillance is recommended

• Pediatric presentation:
• Often more subtle than adult presentation; may include school performance decline, scoliosis (occurs in ~25% of children with CM), gait disturbance, or headaches
• Rapid progression may occur during growth spurts

Neuroimaging (Primary Diagnostic Modality)

• Brain and cervical spine MRI with contrast: Gold standard diagnostic test
• T1 and T2-weighted sagittal imaging: Essential for demonstrating cerebellar tonsillar position relative to foramen magnum
• Diagnostic criterion for Type I: ≥5 mm of cerebellar tonsillar descent below the foramen magnum (measured on sagittal T1 midline images); measurements of 3–5 mm may represent a borderline or anatomic variant
• Assessment of syrinx: Present in 50–80% of symptomatic cases; appears as T2-hyperintense intramedullary cavity in spinal cord; syrinx size correlates with symptom severity
• Evaluation of posterior fossa anatomy: Measure clivus length, basion-dens distance, assess for basilar invagination, and evaluate sagittal spinal canal diameter
• CSF flow characteristics: Phase-contrast cine MRI shows abnormal pulsatile flow patterns through the foramen magnum, demonstrating disrupted CSF dynamics
• Associated abnormalities: Screen for syringobulbia (syrinx extending into brainstem), hydrocephalus, tethered cord, or structural anomalies

• Craniocervical junction imaging:
• Assess atlanto-axial alignment and screen for instability
• Evaluate foramen magnum caliber
• Identify osseous abnormalities (occipital bone hypoplasia, shortened clivus)

Laboratory and Additional Testing

• Routine blood tests: Generally unrevealing; no specific laboratory abnormalities diagnostic of CM
• Genetic testing: Consider in patients with syndromic features (connective tissue disorders, achondroplasia) or positive family history
• Sleep study: If sleep-disordered breathing is suspected (comorbid obstructive sleep apnea reported in 5–15% of CM patients)

Diagnostic Criteria and Classification

Clinical assessment and monitoring

• Structured neurological examination to document baseline deficits (motor, sensory, cranial nerve function, gait, coordination)
• Standardized outcome measures: mJOA (modified Japanese Orthopaedic Association) score for myelopathy severity
• Disability scales: Oswestry Disability Index, SF-36 for functional assessment

Conservative Management (First-Line for Asymptomatic and Mildly Symptomatic Disease)

• Observation and surveillance:
• Asymptomatic patients or those with mild, non-progressive symptoms are typically managed conservatively with clinical follow-up every 6–12 months and neuroimaging every 1–2 years to assess for progression
• The natural history is generally benign; studies show that 70–80% of asymptomatic patients remain clinically stable over prolonged follow-up periods
• Activity modifications: Counseling to avoid strenuous exertion, heavy lifting, and Valsalva-inducing activities (though evidence supporting benefit is limited)

• Symptomatic medical management:
• Acetaminophen or NSAIDs (ibuprofen, naproxen) for headache and neck pain management
• Gabapentin (300–3600 mg daily in divided doses) or pregabalin (150–600 mg daily) for neuropathic pain and dysesthesias
• Tricyclic antidepressants (amitriptyline 10–75 mg nightly) for dual benefit of pain control and mood support
• Muscle relaxants (cyclobenzaprine 5–10 mg at bedtime) for spasticity, though evidence is limited
• Topical agents (lidocaine patches, capsaicin cream) for localized dysesthetic pain
• Osmotic agents: Some practitioners empirically use acetazolamide (250–1000 mg daily) on the theoretical basis of reducing CSF production, though robust evidence is lacking

Surgical Intervention (Indicated for Progressive or Severely Symptomatic Disease)

• Indications for surgery:
• Progressive neurological deficits despite conservative management
• Rapidly enlarging syrinx with associated symptom progression
• Severe, refractory symptoms significantly impacting quality of life
• Symptomatic syrinx with evidence of cord atrophy or damage
• Assessment of surgical candidacy requires demonstration of symptom-syrinx correlation on imaging

• Surgical techniques:
• Suboccipital decompression: Most common approach; involves removal of lamina of C1 (and sometimes C2) and opening of the dura mater; may be performed with or without duraplasty (reinforcement with autograft or allograft dural substitute). Dural opening is increasingly used as it improves CSF flow restoration. Outcomes: 60–80% of patients experience symptom improvement or stabilization; headache most responsive to intervention.
• Duraplasty techniques: Expansion with autologous fascia lata, pericranium, synthetic grafts (Gortex, Alloderm), or allograft dura increases operative morbidity slightly but may improve long-term outcomes for progressive disease
• Syrinx fenestration/drainage: Reserved for cases with tethered spinal cord or arachnoid scarring causing syrinx; direct drainage into subarachnoid space may be performed
• Tethered spinal cord release: If imaging reveals spinal cord tethering, untethering procedure may be performed concurrently
• Foramen magnum decompression with C1 laminectomy ± C2 laminectomy: Standard approach; adequate exposure of the foramen magnum is essential

• Postoperative management:
• Activity restriction for 4–6 weeks post-op; gradual return to normal activities
• Physical therapy for rehabilitation and strengthening
• Imaging surveillance: MRI at 3–6 months post-op to assess syrinx size, then periodically thereafter
• Clinical follow-up: Regular neurological assessment to document functional recovery

Adjunctive Measures

• Management of associated conditions:
• Hydrocephalus: If present, ventriculoperitoneal (VP) shunt placement may improve CM symptoms
• Tethered cord: Neurosurgical untethering indicated if identified
• Syringobulbia: Address underlying anatomic abnormality; monitor for lower cranial nerve deterioration
• Basilar invagination or atlanto-axial instability: Consider stabilization procedures (C1–C2 fusion) if symptomatic instability present

• Sleep apnea management: CPAP or similar positive airway pressure devices if obstructive sleep apnea is diagnosed (may worsen CM symptoms if untreated)

• Genetic counseling: For patients with syndromic CM or positive family history; discuss inheritance patterns and screening of relatives

Neurological Complications

• Progressive myelopathy: Advancing weakness, spasticity, and sensory loss over months to years; most concerning long-term complication. Results from chronic cord compression, ischemia, and gliosis. Management involves surgical decompression before irreversible neuronal damage occurs.

• Syrinx progression: Intramedullary cavity expansion correlates with advancing neurological deficits. Large syrinxes (>3 mm in diameter) associated with worse prognosis. Progressive syrinx despite conservative management warrants surgical intervention.

• Lower cranial nerve deficits: CN IX–XII involvement from direct compression at foramen magnum manifests as dysphagia (aspiration risk), dysarthria, vocal cord paralysis (stridor, respiratory compromise), and lingual atrophy. May improve with decompression surgery; severe swallowing dysfunction may necessitate temporary nasogastric feeding tube or PEG tube placement.

• Syringobulbia: Extension of syrinx into medulla oblongata, causing brainstem symptoms (facial pain, weakness, nystagmus, hearing loss). Prognostically significant; indicates advanced disease.

Systemic and Metabolic Complications

• Scoliosis: Present in ~25% of children and some adults with CM. Etiology multifactorial (chronic myelopathy, anterior horn cell loss, cord tether). May progress rapidly and require orthopaedic intervention (bracing, fusion); surgery should address underlying CM if indicated.

• Spasticity and contractures: Chronic upper motor neuron dysfunction may progress to fixed contractures, complicating **mobility and self-

Buzzwords that name the diagnosis

• Cough/Valsalva-triggered occipital headache in a young adult, worse with straining, sneezing, or neck flexion — the single most characteristic stem opener for Chiari I. Mechanism: transient pressure dissociation across an obstructed foramen magnum.
• "Cape-like" (suspended) loss of pain and temperature with preserved dorsal-column sensation: the syrinx interrupts decussating spinothalamic fibers in the anterior white commissure. Preserved vibration/proprioception distinguishes syringomyelia from a transverse cord lesion.
• Tonsillar descent ≥5 mm below the foramen magnum is the radiographic threshold; 3–5 mm is borderline and often a normal variant. Herniation alone without symptoms is not a disease.

Single best next step

• MRI of the brain and entire cervical spine whenever Chiari is suspected — imaging must extend far enough caudally to capture a syrinx, since syrinx presence and size drive management.
• Do not perform lumbar puncture in suspected symptomatic tonsillar herniation; withdrawing lumbar CSF worsens the craniospinal pressure gradient. This is the classic trap distractor.

The association examiners test

• Chiari II = myelomeningocele + hydrocephalus (Arnold–Chiari), presenting in infancy with inspiratory stridor, apnea, and dysphagia from lower cranial nerve/brainstem traction. Treat the hydrocephalus first (ventricular shunting) before considering posterior fossa decompression.
• Periconceptional folic acid prevents the neural tube defect underlying Chiari II; the USPSTF recommends daily supplementation for all people capable of pregnancy, and ACOG endorses higher-dose supplementation after an affected pregnancy. Prenatal myelomeningocele repair (MOMS trial) reduces later shunt dependence.
• Scoliosis in a child — especially left-convex or with any neurologic sign — should prompt neuraxial MRI to exclude Chiari I with syrinx before it is called idiopathic.

Distractors to avoid

• Chiari I is not associated with myelomeningocele — that is Chiari II by definition.
• Asymptomatic incidental tonsillar ectopia does not warrant prophylactic surgery; surveillance is correct.
• Painless burns or unnoticed hand injuries with areflexic upper-limb weakness point to syringomyelia, not ALS (no sensory loss) or MS (dissemination in space/time on MRI).